Wedbush Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has reiterated an Outperform rating on Tyra Biosciences (NASDAQ:TYRA) and maintained a $28 price target.
May 10, 2024 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll reaffirmed an Outperform rating on Tyra Biosciences, with a price target of $28, indicating a positive outlook on the stock.
The reiteration of an Outperform rating by a reputable analyst like Robert Driscoll, coupled with a maintained price target of $28, suggests a strong bullish sentiment towards Tyra Biosciences. This endorsement could positively influence investor perception and potentially drive the stock's price upward in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100